HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1-infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in 1 subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1-specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1-specific immune responses should be considered as an adjunctive treatment strategy for HIV-1-infected individuals on HAART.
Ortiz
G M
GM
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA.
Nixon
D F
DF
Trkola
A
A
Binley
J
J
Jin
X
X
Bonhoeffer
S
S
Kuebler
P J
PJ
Donahoe
S M
SM
Demoitie
M A
MA
Kakimoto
W M
WM
Ketas
T
T
Clas
B
B
Heymann
J J
JJ
Zhang
L
L
Cao
Y
Y
Hurley
A
A
Moore
J P
JP
Ho
D D
DD
Markowitz
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016655:HIV Core Protein p24 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014766:Viremia / Q000188:drug therapy / Q000276:immunology; D014779:Virus Replication
D019380:Anti-HIV Agents; D016655:HIV Core Protein p24